scholarly journals In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice

2015 ◽  
Vol 43 (11) ◽  
pp. 1646-1654 ◽  
Author(s):  
Kazuto Yasuda ◽  
Cynthia Cline ◽  
Yvonne S. Lin ◽  
Rachel Scheib ◽  
Samit Ganguly ◽  
...  
2021 ◽  
Vol 22 (7) ◽  
pp. 3758
Author(s):  
Balázs Nemes ◽  
Kata Bölcskei ◽  
Angéla Kecskés ◽  
Viktória Kormos ◽  
Balázs Gaszner ◽  
...  

Somatostatin receptor subtype 4 (SST4) has been shown to mediate analgesic, antidepressant and anti-inflammatory functions without endocrine actions; therefore, it is proposed to be a novel target for drug development. To overcome the species differences of SST4 receptor expression and function between humans and mice, we generated an SST4 humanized mouse line to serve as a translational animal model for preclinical research. A transposon vector containing the hSSTR4 and reporter gene construct driven by the hSSTR4 regulatory elements were created. The vector was randomly inserted in Sstr4-deficient mice. hSSTR4 expression was detected by bioluminescent in vivo imaging of the luciferase reporter predominantly in the brain. RT-qPCR confirmed the expression of the human gene in the brain and various peripheral tissues consistent with the in vivo imaging. RNAscope in situ hybridization revealed the presence of hSSTR4 transcripts in glutamatergic excitatory neurons in the CA1 and CA2 regions of the hippocampus; in the GABAergic interneurons in the granular layer of the olfactory bulb and in both types of neurons in the primary somatosensory cortex, piriform cortex, prelimbic cortex and amygdala. This novel SST4 humanized mouse line might enable us to investigate the differences of human and mouse SST4 receptor expression and function and assess the effects of SST4 receptor agonist drug candidates.


2019 ◽  
Vol 5 (12) ◽  
pp. 2003-2013 ◽  
Author(s):  
Takeshi Fuchigami ◽  
Masao Kawasaki ◽  
Ryusuke Koyama ◽  
Mari Nakaie ◽  
Takehiro Nakagaki ◽  
...  
Keyword(s):  

2011 ◽  
Vol 21 (14) ◽  
pp. 4193-4196 ◽  
Author(s):  
Mengchao Cui ◽  
Masahiro Ono ◽  
Hiroyuki Kimura ◽  
Boli Liu ◽  
Hideo Saji

Author(s):  
Verena Heise ◽  
Enikő Zsoldos ◽  
Klaus P. Ebmeier

There is little doubt that the brain changes with time, and all research in psychiatry is predicated on holding age constant in comparing groups of patients or estimating the effect sizes of causal factors. Nevertheless, relatively little is known about the mechanisms that are responsible for translating time into ageing. This chapter tries, after an overview of the principal mechanisms involved in biological ageing, to summarize the age-related changes observable in brains in vivo and to demonstrate the types of investigations that may cast light on such mechanisms in the future. A useful heuristic device to order the multiple potential causes of ageing is the chronic stress–allostatic load model, widely employed in epidemiology, public health medicine, and health psychology. In vivo imaging provides a method to test the translation of intermediate stress markers, such as vascular risk, metabolic syndrome, or allostatic load, into predictors of age-related brain changes.


2020 ◽  
Vol 21 (21) ◽  
pp. 8048
Author(s):  
Marie A. Labouesse ◽  
Reto B. Cola ◽  
Tommaso Patriarchi

Understanding how dopamine (DA) encodes behavior depends on technologies that can reliably monitor DA release in freely-behaving animals. Recently, red and green genetically encoded sensors for DA (dLight, GRAB-DA) were developed and now provide the ability to track release dynamics at a subsecond resolution, with submicromolar affinity and high molecular specificity. Combined with rapid developments in in vivo imaging, these sensors have the potential to transform the field of DA sensing and DA-based drug discovery. When implementing these tools in the laboratory, it is important to consider there is not a ‘one-size-fits-all’ sensor. Sensor properties, most importantly their affinity and dynamic range, must be carefully chosen to match local DA levels. Molecular specificity, sensor kinetics, spectral properties, brightness, sensor scaffold and pharmacology can further influence sensor choice depending on the experimental question. In this review, we use DA as an example; we briefly summarize old and new techniques to monitor DA release, including DA biosensors. We then outline a map of DA heterogeneity across the brain and provide a guide for optimal sensor choice and implementation based on local DA levels and other experimental parameters. Altogether this review should act as a tool to guide DA sensor choice for end-users.


2005 ◽  
Vol 48 (23) ◽  
pp. 7253-7260 ◽  
Author(s):  
Masahiro Ono ◽  
Naoko Yoshida ◽  
Kenichi Ishibashi ◽  
Mamoru Haratake ◽  
Yasushi Arano ◽  
...  

2009 ◽  
Vol 20 (9) ◽  
pp. 726-734 ◽  
Author(s):  
Liv M. Austenaa ◽  
Harald Carlsen ◽  
Kristin Hollung ◽  
Heidi K. Blomhoff ◽  
Rune Blomhoff

2015 ◽  
Vol 100 (7) ◽  
pp. 3197-3206 ◽  
Author(s):  
Marta Bacconi ◽  
Andreas F. Haag ◽  
Antonina Torre ◽  
Andrea Castagnetti ◽  
Emiliano Chiarot ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document